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Abstract
● AIM: To determine which IIRC scheme was used by 
retinoblastoma centers worldwide and the percentage of 
D eyes treated primarily with enucleation versus globe 
salvaging therapies as well as to correlate trends in treatment 
choice to IIRC version used and geographic region.
● METHODS: An anonymized electronic survey was offered 
to 115 physicians at 39 retinoblastoma centers worldwide 
asking about IIRC classification schemes and treatment 
patterns used between 2008 and 2012. Participants were 
asked to record which version of the IIRC was used for 
classification, how many group D eyes were diagnosed, 
and how many eyes were treated with enucleation versus 
globe salvaging therapies. Averages of eyes per treatment 
modality were calculated and stratified by both IIRC 
version and geographic region. Statistical significance 
was determined by Chi-square, ANOVA and Kruskal-Wallis 
tests using Prism.
● RESULTS: The survey was completed by 29% of physicians 
invited to participate. Totally 1807 D eyes were diagnosed. 
Regarding IIRC system, 27% of centers used the Children’s 
Hospital of Los Angeles (CHLA) version, 33% used the 
Children’s Oncology Group (COG) version, 23% used 
the Philadelphia version, and 17% were unsure. The rate 
for primary enucleation varied between 0 and 100% and 
the mean was 29%. By IIRC version, primary enucleation 
rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. 
By geographic region, primary enucleation rates were: 
Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 
10%, US, 8%; and Middle East, 8%. However, systemic 
chemoreduction was used more often than enucleation in 
all regions except Latin America with a mean of 57% per 
center (P<0.0001). 
● CONCLUSION: Worldwide there is no consensus on 
which IIRC version is used, systemic chemoreduction was 
the most frequently used initial treatment during the study 
period followed by enucleation and primary treatment 
modality, especially enucleation, varied greatly with 
regards to IIRC version used and geographic region. 
● KEYWORDS: retinoblastoma; oncology; retina; enucleation; 
chemotherapy; intra-arterial chemotherapy; ophthalmic artery 
chemosurgery; cancer
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INTRODUCTION
T he International Intraocular Retinoblastoma Classification (IIRC) was developed to more accurately describe 
clinical responses to systemic chemotherapy in cases of 
intraocular disease as the Reese-Ellsworth system had been 
designed to describe responses to lateral photon irradiation 
thirty years previously[1]. In this system, retinoblastoma is 
graded “A” through “E”, with group A eyes having limited 
disease and therefore best prognosis and group E eyes having 
extensive disease and a poorer prognosis when managed with 
primary systemic chemotherapy. However, multiple versions 
of the IIRC with different criteria under the same “A” to 
“E” classification scheme exist including the Philadelphia[2], 
Children’s Hospital of Los Angeles (CHLA)[3], and Children’s 
Oncology Group (COG) versions[4]. Furthermore, while 
authors frequently stratify their globe salvage rates by IIRC 
classifications, the majority of papers in the literature fail to 
identify which IIRC version was used[5-24]. Taken together, 
outcome analysis of apparently similarly grouped eyes 
becomes difficult.
This problem is particularly salient for group D retinoblastoma 
eyes. Under the IIRC system, group D eyes are those with 
non-discrete growth or non-localized seeding with a minimum 
distance from the tumor depending on the version used. 
Specifically, the Philadelphia system defines D eyes as tumors 
with “subretinal and/or vitreous seeds >3 mm from the tumor 
margin occupying ≤50% of the globe”[2], while the COG 
system includes in its criteria the presence of vitreous and/
or subretinal seeding in addition to subretinal fluid and also 
increases the radius to >6 mm[4]. The CHLA version defines 
D eyes as any tumor with “exophytic or endophytic qualities, 
diffuse/extensive vitreous or subretinal seeding, and/or retinal 
detachment in >1 quadrant[3]”. Based on these definitions, 
it is clear that a spectrum of disease severity exists across 
IIRC versions for group D eyes. Thus, although alternative 
treatment options including systemic, intra-arterial, intravitreal 
and periocular chemotherapy seemingly offer excellent globe 
salvage rates without higher rates of metastasis or secondary 
cancers[25-28] outcome comparison across the literature is 
challenging, especially when the IIRC version used is not 
specified. On review of the literature, only three of twenty 
papers reporting on outcomes for eyes classified using the IIRC 
specified which version was used in the text[20,23-24]. In addition, 
because most data on globe-salvaging techniques come from 
large retinoblastoma centers, it is currently unclear if they are 
being widely adopted on an international scale[26-31].
Given these observations, the primary aims of this study 
were to 1) determine which IIRC scheme was used by 
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retinoblastoma centers worldwide, 2) determine the percentage 
of D eyes treated primarily with enucleation versus globe 
salvaging therapies, 3) correlate trends in treatment choice to 
IIRC version used and geographic region.
SUBJECTS AND METHODS
A 39-question survey was sent via email to 115 ophthalmologists 
at 39 retinoblastoma centers worldwide using the Survey 
Monkey website (surveymonkey.com). Institutional review 
board (IRB) approval at our institution was obtained prior to 
survey distribution (IRB # WA0064-15). Survey recipients 
were known to be involved in childhood retinoblastoma 
management and were included based on their involvement in 
retinoblastoma care, conferences and forums. 
Participants were asked to record data for group D eyes 
diagnosed in their center between January 1, 2008 and 
December 31, 2012. They were asked to record: the IIRC 
scheme used, the total number of group D eyes, and the 
number of eyes primarily treated with enucleation, intra-
arterial chemotherapy, bridging chemotherapy followed by 
intra-arterial chemotherapy, systemic chemoreduction, external 
beam radiation, or brachytherapy. No personal or institutional 
data were collected, although all participants were asked to 
provide the country in which their practice is located. Relevant 
data from our own center, Memorial Sloan Kettering was also 
collected, entered into the electronic survey and included in 
the overall study data. A copy of the survey can be found as 
supplemental material to this article. 
Survey results were aggregated in an Excel (Version 14.6.6) 
spreadsheet generated by the Survey Monkey website, which 
listed responses from each survey participant anonymously. For 
surveys that were returned incomplete, participants’ responses 
were included in data analysis pertaining to the questions 
answered and excluded from data analysis for questions 
omitted. Data regarding brachytherapy were excluded given an 
exceedingly small sample size (10 eyes total, representing only 
0.6% of total eyes).
The percentage of total D eyes treated with enucleation 
and other globe salvaging therapies was calculated along 
with mean and median values per center for each treatment 
modality. Data pertaining to each treatment modality were then 
grouped by IIRC version and geographic region and the same 
values were calculated. The Chi-square, one-way ANOVA 
and Kruskal-Wallis tests were used to determine statistical 
significance using Prism 6. 
RESULTS
The survey was completed in entirety by 25% of physicians 
invited to participate in the survey and incompletely by an 
additional 8% of physicians. These responses were gathered 
from throughout the United States (11), Asia (7), Europe (4), 
Latin America (4), Africa (2), and the Middle East (1). Nine 
survey participants did not list their center’s location. Totally 
1807 D eyes were reported. Regarding IIRC system, 27% of 
centers used the CHLA version, 33% used the COG version, 
23% used the Philadelphia version, and 17% were unsure 
which version they used. Within the United States, 36% of 
centers used the Philadelphia version, 36% used the Children’s 
Oncology Group version, 18% used the Children’s Hospital of 
Los Angeles Version and 9% did not know which version they used. 
The rate for primary enucleation varied between 0 and 100% 
across centers. Of the aggregate 1807 D eyes reported, 27% 
were primarily enucleated. The mean percentage of eyes 
primarily enucleated per center was 29%, while the median 
was 17%. These values were derived by first calculating the 
percentage of D eyes primarily enucleated in each center and 
then calculating the mean and median of this data set. Twenty- 
six percent of centers did not primarily enucleate any eye and 
26% of centers primarily enucleated greater than 50% of eyes. 
The two largest centers to participate in the study (≥300 eyes) 
enucleated less than 20% of eyes overall. 
Systemic chemotherapy was the most commonly used 
treatment, administered to 53% of all group D eyes reported 
(P<0.0001). The mean percentage of eyes treated with 
systemic chemotherapy per center was 57%, while the median 
was 60%. The use of systemic chemotherapy was followed 
by other globe-salvaging techniques as follows: intra-arterial 
chemotherapy (16%), bridging plus intra-arterial chemotherapy 
(4%) and external beam radiation (1%) (P<0.0001). The 
number of eyes treated with enucleation versus globe-sparing 
techniques for each participating center is depicted in Figure 1. 
This figure includes any participant who at minimum answered 
how many group D eyes were diagnosed and how many of 
these group D eyes were primarily enucleated. 
When stratifying enucleation rates by IIRC system, centers 
using the Philadelphia version had both the greatest number 
of group D eyes diagnosed and the lowest percent of eyes 
Figure 1 Treatment choice by center for all eyes reported.
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primarily enucleated overall (P<0.0001) and per center 
(P=0.03) during the study period. Comparison to centers using 
the CHLA and COG version are shown in Table 1. When 
analyzed by geographic region, the primary enucleation rates 
of group D eyes were lowest in the Middle East (8%) and US 
(8%) (P<0.0001). Enucleation rates for each geographic region 
from this survey study are shown in Table 2 and compared 
to publishedenucleation rates per region in Table 3. Data 
from papers cited elsewhere in this article that only provided 
a combined enucleation rate for groups D and E eyes were 
omitted from Table 3. 
With regards to globe sparing therapies, systemic chemotherapy 
was used most frequently in all geographic regions except 
Latin America, which used enucleation more frequently 
(P<0.0001). Rates for systemic chemotherapy as primary 
treatment modality were: Africa, 83%, Middle East, 75%; 
US, 58%; Asia, 56%; Europe, 43% and Latin America, 32%. 
The use of intra-arterial chemotherapy as primary treatment 
was only reported in the US (28%), Europe (19%) and Latin 
America (4%). Bridging chemotherapy in combination with 
intra-arterial chemotherapy was reported in the Middle East 
(17%), US (6%), Latin America (5%) and Europe (1%). 
External beam radiotherapy was used least frequently and 
reported in Asia (4%), Africa (2%), Latin America (2%), and 
Europe (1%) (P<0.0001). These rates are compared in Figure 2. 
DISCUSSION
Although the IIRC system was developed to better describe 
outcomes for intraocular retinoblastoma managed with 
Table 1 Comparison of group D eyes diagnosed and enucleated when stratified by IIRC version
Country Total D eyes diagnosed % D eyes primarily enucleated (P<0.0001)
Mean % D eyes primarily 
enucleated per center (P=0.03)
Philadelphia 801 8 8
CHLA 473 37 27
COG 274 34 26
Unknown 259 63 62
CHLA: Children’s Hospital of Los Angeles; COG: Children’s Oncology Group.
Table 2 Comparison of group D eyes diagnosed and enucleated when stratified by geographic region
Country Total D eyes diagnosed % D eyes primarily enucleated (P<0.0001)
Median % D eyes primarily 
enucleated per center (P=0.03)
USA 952 8 0
Middle East 12 8 1
Africa 96 10 7
Europe 75 36 7
Asia 394 40 31
Latin America 190 58 49
Table 3 Comparison of enucleation rates observed in our survey study versus published data
Country Our survey enucleation 
rate (%)
Published enucleation 
rate (Avg) Range Dates
USA[24,32-33] 8 13 6-18 2000-2013
Middle East[8] 8 43 43 2001-2007
Africa[5,11,23] 10 96 91-100 2006-2011
Europe[10,18] 36 58 33-82 1995-2011
Asia[6,7,9,13-14,22] 40 55 15-77 1997-2014
Latin America[21] 58 75 75 2007-2014
Figure 2 Comparison of treatment choice stratified by geographic 
region  AFR: Africa; EUR: Europe; ME: Middle East; LA: Latin 
America; IA: Intra-arterial.
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systemic chemotherapy differing versions of this scheme make 
it challenging to compare success among centers, especially if 
the IIRC version is not specified. Based on our review of the 
literature and our survey data, there is no apparent consensus 
regarding which version of the IIRC is used both worldwide 
and within the United States. Moreover, a significant 
percentage of institutions do not even know which system they 
are using. This makes critical review of the literature regarding 
retinoblastoma eyes grouped by IIRC version difficult.
With regards to primary treatment choice for group D 
retinoblastoma, enucleation has historically been the standard 
of care for patients with advanced disease. However, over 
the last three decades, major centers decreased their rates of 
enucleation in favor of globe-salvaging techniques[24,29-30]. 
Further refinements of chemotherapy delivery methods, 
especially recent series using intra-arterial chemotherapy, 
have shown increased rates of ocular salvage even in cases 
of advanced tumors[25-28]. Given this emerging data, it is 
interesting to compare practice patterns between international 
retinoblastoma centers as it is currently unknown whether 
new forms of treatment are available or widely utilized in 
developing countries. 
Based on our survey study, enucleation rates varied greatly 
among centers, with 27% of group D eyes treated primarily 
with enucleation overall. Systemic chemotherapy was the 
most popular primary treatment choice for 53% of group 
D eyes. Intra-arterial chemotherapy, both alone and with 
bridging chemotherapy, and external beam radiation were less 
popular as initial treatment choice.  The utilization of intra-
arterial chemotherapy may reflect the study period, which 
only extended to 2012. As this technique gains popularity with 
time and is explored by other centers its utilization will likely 
increase. This is supported by a study by Grigorovski et al[31] 
that reports three-quarters of international centers regard intra-
arterial chemotherapy as first-line treatment for advanced 
unilateral eyes. Participants were not asked to differentiate 
between bilateral versus unilateral disease in this survey. In 
addition, the survey did not elicit which treatment modalities 
were available to each participant at the time of diagnosis. 
Further survey studies are necessary to evaluate what factors 
contributed to the enucleation rates reported.
When stratifying data by IIRC version, centers using the 
Philadelphia version diagnosed the greatest number of D 
eyes and primarily enucleated the fewest eyes. This may be 
because in comparison to the COG and CHLA IIRC version, 
the Philadelphia version has the lowest cutoff for distance of 
subretinal and/or vitreal seeds away from the tumor and no 
mention of subretinal fluid or retinal detachment[2-4]. Thus, 
some eyes classified under the Philadelphia version as D eyes 
may have been considered C eyes under an alternate scheme. 
In addition, the Philadelphia version is the only classification 
scheme to include a definitive size cutoff for the tumor, setting 
it at ≤50% of the globe for group D eyes. This means that eyes 
with larger tumors above this cutoff would automatically be 
classified as group E under the Philadelphia scheme while 
the same eyes may be considered group D under COG or 
CHLA classification depending on their other qualities. Taken 
together, it follows that eyes containing less advanced tumors 
may have been more comfortably treated with globe-salvaging 
strategies by clinicians, thus possibly explaining the lowest 
percentage of enucleations in eyes classified as group D under 
the Philadelphia version. If a significant difference in ocular 
survival across IIRC version is confirmed by future studies, it 
might support standardization of the IIRC system.
With respect to geographic region, the lowest enucleation rates 
were found in the US (8%) and Middle East (8%). Higher 
enucleation rates were reported in Europe, Asia and Latin 
America. The US enucleation rate of 8% is consistent with 
published data as shown in Table 3. However, all other primary 
enucleation rates calculated from our survey data were lower 
than those found in the literature, including the worldwide 
average per center (29% from our survey versus 57% from 
the literature). Many variables may explain this finding such 
as under representation of regions by participation of a limited 
number of centers (the Middle East was represented by one 
center and Africa by 2 centers) and overrepresentation by 
the USA which had one of the lowest enucleation rates, or 
difference in management patterns between the published 
(including late 1990s and early 2000s) and study (2008-2012) 
time periods. In addition, little data on enucleation rates for 
group D eyes exist for comparison to our results. We cannot 
generalize the results of the few studies from a limited number 
of centers to an entire region and this may also account for 
inconsistencies between our data and reported enucleation 
rates as displayed in Table 3. An alternate hypothesis is that 
inherent bias in survey studies exists and centers with low 
enucleation rates may be more likely to respond to a survey 
regarding enucleation than centers with high rates. However, 
some published data suggest that web-based surveys eliminate 
some of this bias likely due to anonymity[32].
Despite significant advances in the understanding and 
treatment of retinoblastoma, there is limited consensus about 
how to classify and treat advanced tumors. Few centers 
report which IIRC version they use, and when stated, the 
discrepancies among versions make comparing results across 
the literature difficult for readers. Regardless of IIRC version 
used, however, and the success of globe sparing techniques 
such as intra-arterial chemotherapy, the use of enucleation 
as primary treatment for group D retinoblastoma is still 
widespread and variable worldwide. We look forward to future 
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